182
Participants
Start Date
October 13, 2025
Primary Completion Date
October 13, 2028
Study Completion Date
October 13, 2028
Rilvegostomig
Rilvegostomig will be administered as an intravenous (IV) infusion.
AB248
AB248 will be administered via syringe or an IV bag.
Cisplatin
Cisplatin will be administered as SoC as an IV infusion.
Carboplatin
Carboplatin will be administered as SoC as an IV infusion.
Pemetrexed
Pemetrexed will be administered as SoC as an IV infusion.
Paclitaxel
Paclitaxel will be administered as SoC as an IV infusion.
Nab-paclitaxel
Nab-paclitaxel will be administered as SoC as an IV infusion.
Ramucirumab
Ramucirumab will be administered as an IV infusion.
Research Site, Taipei
Research Site, Anderlecht
Research Site, Seongbuk-Gu
Research Site, Leuven
Research Site, Hasselt
Research Site, Seoul
Research Site, Batumi
Research Site, Ankara
Research Site, Seoul
Research Site, Rachathewi
Research Site, Bangkok
Research Site, Belgrade
Research Site, Taipei
Research Site, Marseille
Research Site, Lima
Research Site, Niš
Research Site, Milan
Research Site, Dijon
Research Site, Baltimore
Research Site, Chanthaburi
Research Site, Pavia
Research Site, Madrid
Research Site, Madrid
Research Site, Pozuelo de Alarcón
Research Site, Pamplona
Research Site, Jacksonville
Research Site, Bordeaux
Research Site, Kragujevac
Research Site, Fatih
Research Site, Khon Kaen
Research Site, Taichung
Research Site, Nantes
Research Site, Cleveland
Research Site, Valencia
Research Site, Valencia
Research Site, Detroit
Research Site, Rochester
Research Site, Kuala Lumpur
Research Site, Kuala Selangor
Research Site, Paris
Research Site, Tyler
Research Site, Phoenix
Research Site, Limoges
Research Site, Hat Yai
Research Site, Kuching
Research Site, Santa Rosa
Research Site, Shenyang
Research Site, Shanghai
Research Site, Shanghai
Research Site, Jinan
Research Site, Singapore
Research Site, Fuzhou
Research Site, Chongqing
Research Site, Wuhan
Research Site, Wuhan
Research Site, Guangzhou
Research Site, Shenzhen
Research Site, Chengdu
Research Site, Deyang
Research Site, Providence
Research Site, Barretos
Research Site, Fortaleza
Research Site, Natal
Research Site, Pelotas
Research Site, Porto Alegre
Research Site, São Paulo
Research Site, São Paulo
Research Site, Nice
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Tbilisi
Research Site, Roma
Research Site, Bunkyō City
Research Site, Kurume-shi
Research Site, Toyoake-shi
Research Site, Chisinau
Research Site, Amsterdam
Research Site, Groningen
Research Site, Leiden
Research Site, Koszalin
Research Site, Lodz
Research Site, Olsztyn
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Ankara
Lead Sponsor
AstraZeneca
INDUSTRY